Pre-exposure prophylaxis, or PrEP, is a strategy that involves the use of antiretroviral medications (ARVs) to reduce the risk of HIV infection via sexual exposure. The US Food and Drug Administration (FDA) has approved daily oral TDF/FTC as PrEP. Additional background information available here.
Priorities for the
AVAC's Playbook sets out top
strategic goals and priorities in HIV
prevention for ourselves—and for the world.
Here's what we have to say about PrEP. For
more, visit www.avac.org/playbook.
What's NewVOICE Trial Results Underscore Need to Accelerate Development of Additional HIV Prevention Options for Women
- PrEP strategies remain a valuable tool; read the AVAC statement
- Background on VOICE trial and reaction to results
- Visit prepwatch.org for further resources
- Listen to the trial investigators of VOICE discuss their results
- Read about how researchers are working to improve adherence in trials and during real world use in the latest issue of PxWire
The Latest Information on PrEP Research
- ARV-Based Prevention Research and Development Product Pipeline (PDF), (JPEG)
- Ongoing and Planned PrEP Trials and Demonstration Projects (PDF), (JPEG)
- PrEP Trials Efficacy and Adherence (PDF), (JPEG)
PrEP Update: From the
American Journal of Preventative
- From Efficacy to Impact: An advocate's agenda for HIV pre-exposure prophylaxis implementation by AVAC's Emily Bass and Mitchell Warren
- E-mail firstname.lastname@example.org for copies of the article
Guidance on PrEP
- Visit prepwatch.org for guidelines from the World Health Organization and various countries
- Our recent webinar, New Guidelines on Daily Oral PrEP has slides and audio available
- Guidance slides and table
Background on PrEP
Pre-exposure prophylaxis, or PrEP, is a strategy that involves use of antiretroviral medications (ARVs) to reduce the risk of HIV infection via sexual exposure.
All of the current effectiveness and follow-on trials are testing tenofovir-based regimens—using either TDF/FTC (an antiretroviral containing tenofovir (TDF) and emtricitabine (FTC) that is sold under the brand name Truvada) or TDF (an antiretroviral pill marketed under the brand name Viread).
Based on the data that have been collected to date the US Food and Drug Administration (FDA) announced its approval of daily oral TDF/FTC for PrEP. This is the first ARV to be approved for HIV prevention in HIV-negative adults.
You can get around the PrEP section via the links below (each list includes a few key resources from the section). Refine your search for PrEP materials on our research literacy database.
Ongoing Trials and Recent Results
In-depth PrEP Resources
- Links to guidance documents and guidelines on prepwatch.org
- Guidance slides and table
- PrEP-related webinars
- Search for specific PrEP materials in our research literacy database
updated: March 4, 2013